Miyaji, Mai J.
Ide, Kentaro
Takashima, Kohei
Maeno, Mikiko
Krallman, Kelli A.
Lazear, Danielle
Goldstein, Stuart L.
Article History
Received: 6 December 2021
Revised: 5 February 2022
Accepted: 7 February 2022
First Online: 28 March 2022
Declarations
:
: MJM serves as a consultant to Lowell Therapeutics, Inc, which has licensed NM in the US. At the current time, NM is not approved for marketing in the US. Lowell did not have input into the design of this study, access to the raw data or development of any aspect of this manuscript.